GSK (LON:GSK) Stock Rating Reaffirmed by Citigroup

GSK (LON:GSK)‘s stock had its “buy” rating reaffirmed by Citigroup in a research note issued to investors on Monday, MarketBeat Ratings reports. They presently have a GBX 2,100 ($26.64) target price on the stock. Citigroup’s price objective suggests a potential upside of 31.66% from the stock’s current price.

GSK has been the topic of a number of other research reports. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research report on Tuesday, June 18th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 ($24.74) price target on shares of GSK in a research note on Tuesday, June 18th. Shore Capital reiterated a “buy” rating on shares of GSK in a research note on Wednesday, June 12th. Finally, Barclays reiterated an “equal weight” rating and issued a GBX 1,725 ($21.88) price target on shares of GSK in a research note on Tuesday, May 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, GSK presently has a consensus rating of “Hold” and a consensus target price of GBX 1,725.63 ($21.89).

GSK Price Performance

Shares of LON GSK opened at GBX 1,595 ($20.23) on Monday. The business’s 50 day moving average price is GBX 1,688.19 and its two-hundred day moving average price is GBX 1,630.16. The company has a market cap of £65.08 billion, a PE ratio of 1,463.30, a price-to-earnings-growth ratio of 1.19 and a beta of 0.27. The company has a quick ratio of 0.73, a current ratio of 0.87 and a debt-to-equity ratio of 134.34. GSK has a twelve month low of GBX 1,302.60 ($16.52) and a twelve month high of GBX 1,823.50 ($23.13).

Insider Transactions at GSK

In related news, insider Wendy Becker purchased 446 shares of the stock in a transaction dated Thursday, June 20th. The stock was bought at an average cost of GBX 1,614 ($20.47) per share, for a total transaction of £7,198.44 ($9,131.60). Company insiders own 1.60% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.